Introduction {#S0001}
============

Pulmonary pleomorphic carcinoma (PPC) is an uncommon heterogeneous tumor of non-small cell lung carcinomas (NSCLCs). The reported incidence of PPC in the literature has ranged from 0.1% to 1.6% of all lung cancer \[[@CIT0001]--[@CIT0003]\]. According to the WHO classification of lung tumors, PPC is defined as a carcinoma consisting of spindle and giant cells alone or NSCLC combined with a sarcomatoid tumor component of at least 10% \[[@CIT0004]--[@CIT0006]\]. Several studies have reported that many lung adenocarcinomas (ADs) are highly sensitive to tyrosine kinase inhibitors (TKIs), and most of these patients are from the Asian, female, nonsmoker population \[[@CIT0007]--[@CIT0010]\]. However, the information on the epidermal growth factor receptor (EGFR) and Kirsten rat sarcoma viral oncogene (KRAS) mutation status of PPC is sparse and controversial because of its rarity. And whether EGFR inhibitor therapy might be effective in patients with PPC is not yet clear. Italiano *et al*. reported the lack of EGFR mutation and high rate of KRAS mutation. Most patients with PPC were not likely to benefit from EGFR-targeted therapies \[[@CIT0011], [@CIT0012]\]. Nonetheless, a number of other studies show the existence of EGFR mutation, and a low KRAS mutation incidence rate \[[@CIT0013]--[@CIT0015]\]. Factors such as the small series of patients, and geographical or racial variation, might explain these differences. Moreover, the incidence of EGFR mutations in Chinese PPC patients has not been defined.

In the current study, therefore, we examine the EGFR and KRAS mutation status in a relatively large series of surgically treated PPC specimens, and investigate the association of several clinical variables with the EGFR and KRAS mutation, in order to identify useful information on patient selection for targeted therapy.

Material and methods {#S0002}
====================

Tumor cases {#S20003}
-----------

Between February 2007 and February 2011, a total of 6990 patients with NSCLC were treated surgically in the Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Shanghai, China. A total of 110 cases of PPC (1.57%) and 225 other cases of NSCLC, i.e., 113 ADs, 40 squamous cell carcinomas (SQs), 55 adenosquamous carcinomas (ADSQs) and 17 large cell carcinomas (LCCs) of lung, were collected and diagnosed strictly using the WHO classification \[[@CIT0004]\]. In every case, we used formalin-fixed and paraffin-embedded tissues from resections. All slides were reviewed blindly by 2 pathologists. In addition, in each case of PPC, the epithelial immunophenotype of the tumor was confirmed using markers of AD (TTF1, SPA and SPB) and SQ (p63, CK5/6 and 34βE12). We also performed additional immunohistochemical (IHC) stains for Vimtion to demonstrate sarcoma. Clinical information, including patient sex, age at diagnosis, and smoking history was obtained for all these cases. Testing for EGFR and KRAS mutations was successfully analyzed in 70 PPCs and 225 other cases. This study was approved by the institutional review boards, and appropriate written informed consent was obtained from all patients.

DNA extraction and sequencing analysis {#S20004}
--------------------------------------

For mutation detection, DNA was extracted from the formalin-fixed, paraffin-embedded tumor sections. EGFR exon 19 and 21 and KRAS codon 12 and 13 mutations were detected using direct-sequencing polymerase chain reaction as previously described \[[@CIT0016]\]. To minimize necrosis and normal cell genomic DNA contamination, tumor areas were selected by manual microdissection of HE stained slides.

Statistical analysis {#S20005}
--------------------

The data were analyzed using SPSS version 17.0 for Windows. Correlations between clinicopathologic and molecular factors were determined using the χ^2^ and Fisher exact tests. The Mann-Whitney *U* test was used to detect significant differences in patient age and tumor size. Overall survival was defined as the time from surgical resection until the date of death or last follow-up for patients who remained alive. Survival curves were analyzed using the Kaplan-Meier method and compared by using the log-rank test. Univariate and multivariate relative risk were calculated using Cox proportional hazards regression. Two-sided *p* values of less than 0.05 were considered to indicate statistical significance.

Results {#S0006}
=======

Clinicopathologic characteristics of the 110 pulmonary pleomorphic carcinomas and comparison with other non-small cell lung carcinomas {#S20007}
--------------------------------------------------------------------------------------------------------------------------------------

Clinicopathological characteristics of all 110 PPC and other NSCLC patients are compiled in [Table 1](#T0001){ref-type="table"}. Briefly, the case series included 92 men and 18 women (M: F ratio 5: 1), aged from 38 to 78 years (median 62 years). There were 39 smokers, and 71 never smokers. The median diameter of the tumor was 4.5 cm (1--14 cm). The locations of the lesions were as follows: in 24 cases they were in the central, in 84 cases in the peripheral, and in 2 cases in both locations.

###### 

Clinicopathologic characteristics of the 110 pulmonary pleomorphic carcinomas and the comparison with other NSCLCs

  Characteristic              Pleomorphic carcinoma *n* = 110 (%)   Other NSCLC *n* = 225 (%)   *p*
  --------------------------- ------------------------------------- --------------------------- -------
  Age (y)                                                                                       0.027
   median                     62                                    59                          
   range                      38--78                                30--79                      
  Sex                                                                                           0.001
   male                       92 (83.5)                             137 (60.9)                  
   female                     18 (16.5)                             88 (39.1)                   
  Smoking history                                                                               0.039
   smoker                     39 (37.4)                             55 (24.4)                   
   never smoker               71 (62.6)                             170 (75.5)                  
  Tumor size (cm)                                                                               0.000
   median                     4.5                                   3                           
   range                      1--14                                 0.4--12                     
  Tumor site                                                                                    0.251
   central                    24 (21.7)                             67 (29.8)                   
   predilection               84 (76.5)                             156 (69.3)                  
   central and predilection   2 (1.7)                               2 (0.89)                    

NSCLC -- non-small cell lung carcinoma

With respect to the comparison of clinicopathologic features, higher age (*p* = 0.027), male sex (*p* = 0.001), smoker (*p* = 0.039), and larger tumor size (*p* = 0.000) were significantly more common in the group of 110 PPCs than in the other group of 225 NSCLCs ([Table 1](#T0001){ref-type="table"}), but the difference of tumor site was not statistically significant (*p* = 0.251).

Histologic features and mutational analysis of 70 pulmonary pleomorphic carcinomas {#S20008}
----------------------------------------------------------------------------------

Sequence analysis of EGFR and KRAS genes was performed on 70 PPCs. On the basis of microscopic examination and IHC staining results, we could identify 18 tumors consisting of spindle cells and giant cells alone, and 52 contained identifiable epithelial components (36 cases showed AD, 7 had SQ, 8 had ADSQ and 1 had LCC).

We identified 11 mutations (15.7%) in EGFR and 10 mutations (14.3%) in KRAS. In particular, EGFR mutations consisted of 2 frame deletions in exon 19 (E746_A750del), and 9 amino acid substitutions in exon 21 (L858R). All KRAS codon 12 and 13 mutations were missense mutations (G12C in 5 cases, G12D in 2, G12V in 1, G12A in 1, and G13C in 1), and all these patients were non-smokers. No mutations were observed simultaneously in both EGFR and KRAS genes ([Table 2](#T0002){ref-type="table"}). Also, 10 PPCs with EGFR mutated had an identifiable epithelial component (6 ADs, 3 ADSQ and 1 SQ) and 1 was classified as pure PPC consisting only of spindle and giant cells. KRAS mutation was found in 8 cases with an epithelial component (6 ADs, 1 ADSQ and 1 SQ), and 2 showed only mesenchymal elements ([Table 3](#T0003){ref-type="table"}).

###### 

Mutational analysis and clinicopathologic findings of pulmonary pleomorphic carcinomas and comparison of the mutations with those of other NSCLCs

  Variable                    *N*   EGFR mutation (%)   *p*     KRAS mutation (%)   *p*
  --------------------------- ----- ------------------- ------- ------------------- -------
  Age                                                   0.461                       0.02
   \< 65                      44    8 (18.2)                    3 (6.8)             
   ≥ 65                       26    3 (11.5)                    7 (26.9)            
  Gender                                                0.011                       0.19
   male                       61    7 (11.5)                    10 (16.4)           
   female                     9     4 (44.4)                    0 (0.0)             
  Tumor location                                        0.557                       0.433
   central                    17    4 (23.5)                    4 (23.5)            
   predilection               52    7 (13.5)                    6 (11.5)            
   central and predilection   1     0 (0.0)                     0 (0.0)             
  Tumor size (cm)                                       0.324                       1.00
   \< 3                       14    1 (7.14)                    2 (14.3)            
   ≥ 3                        56    10 (17.8)                   8 (14.3)            
  Smoking status                                        0.775                       0.074
   never                      55    9 (16.4)                    10 (18.2)           
   ever                       15    2 (13.3)                    0 (0.0)             
  Stage                                                 0.606                       0.209
   I                          29    4 (13.8)                    6 (20.7)            
   II                         14    2 (14.3)                    3 (21.4)            
   III                        17    2 (11.8)                    0 (0.0)             
   IV                         10    3 (30)                      1 (10)              
  Histologic component                                  0.645                       0.973
   AD                         36    10 (27.8)                   6 (16.7)            
   SQ                         7     1 (14.3)                    1 (14.3)            
   ADSQ                       8     2 (25)                      1 (12.5)            
   LCC                        1     0 (0.00)                    0 (0.00)            
  mixed                       18    1 (5.56)                    2 (11.1)            
  Other NSCLC vs. PPC                                                               
   AD                         113   48 (42.5)           0.000   5 (4.42)            0.025
   SQ                         40    1 (2.5)             0.053   2 (5.0)             0.205
   ADSQ                       55    21 (38.2)           0.007   2 (3.6)             0.065
   LCC                        17    0 (0.0)             0.112   0 (0.0)             0.199

###### 

Histologic features and survival of 21 pulmonary pleomorphic carcinomas with EGFR and KRAS mutations

  Patient   Age/Sex   Size   Epithelial component   Sarcoma component   EGFR mutation   KRAS mutation   OS (months)   Outcome   Stage
  --------- --------- ------ ---------------------- ------------------- --------------- --------------- ------------- --------- ------------
  1         59/F      1.8    AD                     spindle             E746-A750del                    12            live      T2N0M0IB
  2         60/F      3      AD                     mixed               E746-A750del                    12            live      T2N2M1IV
  3         51/M      4      AD                     spindle             L858R                           15            live      T2N0M1IV
  4         58/M      3.5    AD                     mixed               L858R                           3             dead      T2N2M0IIIA
  5         55/M      5      ADSQ                   spindle             L858R                           NA            NA        T2N1M0IIB
  6         65/F      5      AD                     mixed               L858R                           NA            NA        T3N0M0IIB
  7         64/M      4      AD                     giant               L858R                           7             dead      T4N1M1IV
  8         63/M      5      ADSQ                   giant               L858R                           16            live      T2N0M0IB
  9         77/F      4      ADSQ                   mixed               L858R                           No            no        T2N2M0IIIA
  10        78/M      4.5    SQ                     mixed               L858R                           15            live      T2N0M0IB
  11        53/M      5.5                           mixed               L858R                           NA            NA        T2N0M0IB
  12        55/M      11     AD                     mixed                               G12A            NA            NA        T2N1M0IIB
  13        64/M      8      AD                     mixed                               G12C            34            live      T2N0M0IB
  14        56/M      5.5    AD                     mixed                               G12C            7             dead      T3N0M0IIB
  15        66/M      3      SQ                     mixed                               G12C            NA            NA        T2N0M0IB
  16        75/M      7      AD                     mixed                               G12C            6             live      T2N2M1IV
  17        70/M      4                             mixed                               G12C            14            live      T2N0M0IB
  18        71/M      2.5    AD                     giant                               G12D            24            live      T2N0M0IB
  19        68/M      6.5    ADSQ                   giant                               G12D            NA            NA        T3N0M0IIB
  20        66/M      7.5                           mixed                               G12V            10            dead      T2N1M0IIB
  21        75/M      1      AD                     spindle                             G13C            10            dead      T1N0M0IA

AD -- adenocarcinoma; SQ -- squamous cell carcinoma; ADSQ -- adenosquamous carcinoma; mixed -- spindle and giant cell carcinoma; OS -- overall survival; NA -- not available

For most mutated patients, different areas corresponding to the epithelial and sarcomatoid components were intimately admixed. Only in two EGFR and one KRAS mutated cases (patients 1, 5 and 19) were the two elements clearly distinct from each other. Therefore, we were able to easily select by manual microdissection, and analyze independently, both the epithelial and the sarcomatoid elements. The same EGFR and KRAS mutations were detected in the two different histological components in all three cases.

Comparison of EGFR and KRAS mutations with those of other non-small cell lung carcinomas {#S20009}
----------------------------------------------------------------------------------------

In comparison with PPCs, there was a higher EGFR mutation rate (42.5%) and lower KRAS mutation rate (4.42%) in the AD group, and the difference was significant (*p* = = 0.000). When the rates of EGFR mutation between PPC and SQ groups were compared alone, near significance was achieved (*p* = 0.053). Moreover, ADSQ group had a higher mutation rate of EGFR (*p* = 0.007) than PPC group, whereas the statistical significance between the two groups in KRAS mutation rate was borderline (*p* = 0.065) ([Table 2](#T0002){ref-type="table"}). Further, we compared the different type of KRAS mutation in these patients. The most frequent type of base change was a G→T transversion (12 of 19 mutations). Two of the KRAS mutations were G→C transversions and 5 were G→A transitions. Still, only three of the patients were ex-smokers (2 ADs with G→A mutation and 1 ADSQ with G→T mutation) ([Table 4](#T0004){ref-type="table"}).

###### 

Relationship between KRAS mutation type and smoking history in NSCLCs

  NSCLCs   KRAS mutation type   Smoking history
  -------- -------------------- -----------------
  PPC      G12A (GGT→GCT)       no
  PPC      G12C (GGT→TGT)       no
  PPC      G12C (GGT→TGT)       no
  PPC      G12C (GGT→TGT)       no
  PPC      G12C (GGT→TGT)       no
  PPC      G12C (GGT→TGT)       no
  PPC      G12D (GGT→GAT)       no
  PPC      G12D (GGT→GAT)       no
  PPC      G12V (GGT→GTT)       no
  PPC      G13C (GGT→TGT)       no
  AD       G12C (GGT→TGT)       no
  AD       G12D (GGT→GAT)       yes
  AD       G12D (GGT→GAT)       yes
  AD       G12V (GGT→GTT)       no
  AD       G12V (GGT→GTT)       no
  SQ       G12R (GGT→CGT)       no
  SQ       G12S (GGT→AGT)       no
  ADSQ     G12C (GGT→TGT)       yes
  ADSQ     G12C (GGT→TGT)       no

PPC -- pulmonary pleomorphic carcinoma; AD -- adenocarcinoma; SQ -- squamous cell carcinoma; ADSQ -- adenosquamous carcinoma

Relationship between EGFR and KRAS mutations and clinicopathologic variables {#S20010}
----------------------------------------------------------------------------

We assessed the relationship between EGFR and KRAS mutations and the clinicopathologic variables listed in [Table 2](#T0002){ref-type="table"}. No significant association was observed between mutation status and smoking history, tumor size, site, stage and histologic components. There was a statistically significant association between the frequency of EGFR mutations and sex (44.4% in females versus 11.5% in males, *p* = 0.011). KRAS mutations were more often found in old age (26.9% of cases at age 65 or older, *p* = 0.02). Additionally, all KRAS mutations occurred in non-smokers.

Prognosis and overall survival {#S20011}
------------------------------

Complete follow-up information was available for 48 cases of PPC. The 5-year survival rate and median overall survival (OS) time were 40% and 36.68 months, respectively. Of these patients, 25 (52.08%) died of disease, with a follow-up ranging from 1 to 51 months; 23 patients (47.92%) were alive, with a follow-up ranging from 23 to 64 months. In univariate analysis, OS was negatively influenced by advanced stage (I--II vs. III--IVA, *p* = 0.000) and tumor size (*p* = 0.012). None of the other analyzed variables, namely gender, age, lymph node metastasis, smoking history, tumor necrosis, location and EGFR/KRAS mutation, had a significant influence on OS. The multivariate analysis confirmed age (*p* = 0.019), tumor size (*p* = 0.044) and stage (*p* = 0.000) as independent variables for OS ([Table 5](#T0005){ref-type="table"}).

###### 

Univariate and multivariate analyses concerning PPC (*n* = 48)

  Variables                             Univariate *p* value   Multivariate           
  ------------------------------------- ---------------------- -------------- ------- --------------
  male vs. female                       0.992                  0.964          0.961   0.169--5.453
  age (y) ≥ 65 vs. \< 65                0.081                  0.019          0.297   0.108--0.816
  tumor size ≥ 3 cm vs. \< 3 cm         0.012                  0.004          0.255   0.068--0.962
  with vs. without tumor necrosis       0.053                  0.239          0.549   0.202--1.489
  early stage vs. late stage            0.000                  0.000          0.061   0.020--0.183
  with vs. without EGFR/KRAS mutation   0.709                  0.649          0.857   0.443--1.661
  smoking vs. no smoking                0.516                  0.919          1.066   0.310--3.672

HR -- hazard ratio; CI -- confidence interval

[Table 3](#T0003){ref-type="table"} shows clinicopathological findings and survival of 21 patients with EGFR and KRAS mutations. The survival data were available for 7 EGFR and 7 KRAS mutated patients. None of the correlations between the 2 groups in OS were statistically significant (*p* = 0.88). More significantly, patient 2 with stage IV disease, a woman who had an exon 19 deletion mutation (E746_A750del), was treated with gefitinib and achieved stable disease. This improvement has lasted for approximately 9 months, and follow-up is underway.

Discussion {#S0012}
==========

Pulmonary pleomorphic carcinoma of the lung is rare. In the current study, we collected a relatively large number of PPCs to better define their clinicopathologic features and explored the relationship between EGFR and KRAS mutation status and multiple variables. In agreement with a previous work on PPCs \[[@CIT0002]\], it accounted for 1.57% (115/6990) of surgically resected NSCLC cases in our department, prevailing in males as a large peripheral lesion. The smokers in our series comprised 37.4% (43/115) and the incidence rate is lower than in other reports \[[@CIT0002], [@CIT0003]\]. Recently, Mochizuki *et al*. mentioned that PPC has distinctive clinicopathological features compared with other NSCLCs \[[@CIT0017]\]. Consistent with their report, our analysis demonstrates a higher number of male smokers, older age and larger tumor size.

Since EGFR and KRAS genes were the most clinically relevant molecular biomarkers in NSCLC, we examined the two key oncogenes' characteristics in 70 resected PPCs. Activating EGFR mutations were seen in 11 patients (15.7%), whereas KRAS mutations were identified in 10 patients (14.3%). Our results revealed that the EGFR mutation rate of PPC is lower than that of AD and ADSQ, but might be higher than that of SQ. The KRAS positive rates are largely concordant with the recently evaluated value of 9--22% in PPC patients \[[@CIT0013]--[@CIT0015]\]. Some investigators have also noted that patients with single classical mutations (del-19 or L858R) show a better response to gefitinib than those without the classical mutations \[[@CIT0018], [@CIT0019]\]. In our study, we identified 10 classical mutations; among these, 2 cases had exon 19 deletions and 8 had L858R point mutations. These results suggested that mutational analysis in patients with PPC should be considered before deciding on a course of treatment. In addition, although there is a male preponderance in PPC, EGFR mutations were also more frequent in females (*p* = 0.011). Consequently, women should be high-priority candidates for EGFR mutation screening. Additionally, in our cohort, 2 tumors with a non-AD component had activating EGFR mutations. Thus, the distribution of EGFR mutation was not associated with the type of malignant epithelial components. Also, KRAS mutations occurred in different subtypes of PPC. Still, we found that KRAS mutation was more frequently detected in older patients than younger patients (age ≥ 65 vs. \< 65) (*p* = 0.02).

With regard to the histogenesis of PPC, two possible pathways have been proposed, divided into monoclonal and polyclonal pathways. Kyoichi Kaira *et al*. described three patients with two different histologic types exhibiting EGFR mutations. Their cases revealed that the adenocarcinomatous component had an EGFR mutation and the sarcomatoid component did not \[[@CIT0020]\]. In our series, in contrast, we found that both epithelial and sarcomatoid components carried identical EGFR and KRAS mutations, favoring the contention that PPCs were monoclonal in origin \[[@CIT0016], [@CIT0021]\].

Another interesting finding is the lack of association between KRAS mutation and smoking. In our studies, even though it was not statistically significant (*p* = 0.074), non-smokers tended to exhibit KRAS mutations more commonly (10/55, 18.2%) than smokers (0/15, 0.0%). In addition, in comparison with other NSCLCs, smokers were more frequent in the PPC group (*p* = 0.039). Consequently, we speculated that although smoking is a risk factor for the development of PPC, it may be less strongly associated with KRAS mutations in Chinese patients, arguing against the notion that a11 KRAS mutations are confined to smokers \[[@CIT0015]\].

Ahrendt *et al*. reported that in KRAS transversions (substituting a pyrimidine for a purine, or a purine for a pyrimidine) are more common than transitions (substituting a purine for a purine, or a pyrimidine for a pyrimidine), and KRAS mutations were significantly more frequent in lung ADs from smokers compared with those from nonsmokers (43% vs. 0%; *p* = 0.001) \[[@CIT0022]\]. Riely *et al*. found that KRAS transversion mutations (G→T or G→C) were more common in smokers with lung AD \[[@CIT0023]\]. In contrast, our studies demonstrated that KRAS mutations in AD were present in only 5 (4.42%) patients. Of the 5 mutations, 2 in smokers were transition mutations and 3 in non-smokers were transversion mutations. Also, we found that most never smokers have transversion mutations (G→T) in PPCs and other NSCLCs. The discrepancy might be attributed to geographical or racial differences in these studies. However, the distinct profile of KRAS mutations observed here in never smokers further suggests that while some mutations in KRAS are associated with cigarette smoking, KRAS tumor status cannot be easily predicted on the basis of smoking history alone.

Several researchers \[[@CIT0024]--[@CIT0026]\] have reported that gefitinib was effective in PPC patients with L858R EGFR mutation. In our series, one patient who had a deletion mutation in exon 19 of EGFR and was treated with gefitinib achieved SD. These findings may suggest that gefitinib is effective in PPC with EGFR mutation. Our study also indicated that sex, smoking history, lymph node status, mutation type, tumor size and site did not have an impact on length of survival, whereas old age and late stage may have significant value in predicting a poor prognosis.

In summary, we observed a similar EGFR and KRAS mutation rate in Chinese PC patients. Our findings further confirmed that some patients with PPC may possess active EGFR mutations and benefit from EGFR-targeted therapies. Of note, EGFR mutations in PPC were commonly identified in women; therefore women should be high-priority candidates for EGFR mutation screening.

The authors declare no conflict of interest.

This work was supported by the Fundamental Research Funds for the Central Universities (grant No. 1511219018) and by the grant from Youth Research Project of Shanghai Municipal Health Bureau (grant No. 20124y088).
